N. Roche (Paris, France), A. Mathioudakis (Manchester, United Kingdom)
The TRIFLOW study; A randomised, cross-over study evaluating the effects of inhaled beclometasone/formoterol/glycopyrronium (BDP/F/G) on hyperinflation in COPD
D. Singh (Manchester, United Kingdom), C. Panainte (Manchester, United Kingdom), N. Khan (Manchester, United Kingdom), J. Dean (Manchester, United Kingdom)
|   |
COPD exacerbation rates by month in the ETHOS trial with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels
F. Martinez (New York, NY, United States of America), K. Rabe (Grosshansdorf, Germany), G. Ferguson (Farmington Hills, MI, United States of America), C. Wang (Beijing, China), D. Singh (Manchester, United Kingdom), J. Wedzicha (London, United Kingdom), R. Trivedi (Durham, NC, United States of America), E. St Rose (Morristown, NJ, United States of America), S. Ballal (Morristown, NJ, United States of America), J. Mclaren (Gaithersburg, MD, United States of America), P. Darken (Morristown, NJ, United States of America), M. Aurivillius (Gothenburg, Sweden), C. Reisner (Morristown, NJ, United States of America), P. Dorinsky (Durham, NC, United States of America)
| |
TriOptimize VII: Improvement of health-related quality of life after 3 months treatmentwith extrafine single inhaler triple therapy in COPD patients in a real-world setting.
C. Geßner (Leipzig, Germany), S. Bahari Javan (Hamburg, Germany), R. Hövelmann (Hamburg, Germany), G. Georges (Cary, United States of America), K. Melchior (Hamburg, Germany), C. Criée (Bovenden, Germany)
| |
Effect of triple therapy with extra-fine BDP/FF/GB pMDI vs non-triple maintenance therapies on severe COPD exacerbations. A pooled analysis of the TRILOGY, TRINITY and TRIBUTE studies.
D. Singh (Manchester, United Kingdom), E. Clini (Reggio Emilia, Italy), A. Papi (Ferrara, Italy), A. Piraino (Parma, Italy), E. Nudo (Parma, Italy), A. Guasconi (Parma, Italy), G. Georges (Parma, Italy), J. Vestbo (Manchester, United Kingdom)
| |
Initial treatment with tiotropium/olodaterol improves physical inactivity in patients with treatment-naïve COPD
K. Takahashi (Saga, Japan), M. Uchida (Saga, Japan), G. Kato (Saga, Japan), A. Takamori (Saga, Japan), H. Sadamatsu (Saga, Japan), M. Tanaka (Saga, Japan), R. Tajiri (Saga, Japan), H. Inoue (Saga, Japan), T. Kinoshita (Fukuoka, Japan), K. Kojima (Saga, Japan), M. Yoshida (Fukuoka, Japan), H. Kobayashi (Saga, Japan), H. Tashiro (Saga, Japan), S. Hayashi (Fukuoka, Japan), A. Kawaguchi (Saga, Japan), N. Sueoka-Aragane (Saga, Japan), T. Kawayama (Fukuoka, Japan)
| |
INTREPID study: Once-daily single-inhaler fluticasone furoate/umeclidinium/vilanterol vs multiple-inhaler triple therapy; sub-analysis by prior medication strata
C. Compton (Brentford, Middlesex, United Kingdom), S. Worsley (Stevenage, Hertfordshire, United Kingdom), D. Midwinter (Stockley Park West, Uxbridge, Middlesex, United Kingdom), A. Ismaila (Collegeville, PA (USA) and Hamilton, ON (Canada), United States of America), K. Beeh (Wiesbaden, Germany), V. Di Boscio (Brentford, Middlesex, United Kingdom), J. Kocks (Groningen (Netherlands), Groningen (Netherlands) and Singapore (Singapore), Netherlands), J. Marin (Zaragoza, Spain), M. Tabberer (Stockley Park West, Uxbridge, Middlesex, United Kingdom), N. Snowise (Brentford, Middlesex and London, United Kingdom), D. Halpin (Exeter, United Kingdom)
| |
Characterising patients with COPD by baseline short-acting ß2-agonist (SABA) use: a post hoc analysis of the EMAX trial
E. Kerwin (Medford, OR, United States of America), I. Boucot (Brentford, Middlesex, United Kingdom), L. Bjermer (Lund, Sweden), F. Maltais (Québec, QC, Canada), P. Jones (Brentford, Middlesex, United Kingdom), L. Tombs (Stockley Park West, Uxbridge, Middlesex, United Kingdom), D. Lipson (Collegeville and Philadelphia, PA, United States of America), C. Compton (Brentford, Middlesex, United Kingdom), C. Vogelmeier (Marburg, Germany)
| |
Efficacy and safety of adding erdosteine in acute exacerbations of COPD (AECOPD): a comparative analysis with the standard treatment
M. Moretti (Pisa (PI), Italy), E. Pozzi (Paderno, Milano,, Italy)
| |
Exacerbation benefit by blood eosinophil counts with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial: a subgroup analysis
K. Rabe (Kiel, Germany), F. Martinez (New York, NY, United States of America), G. Ferguson (Farmington Hills, MI, United States of America), C. Wang (Beijing, China), D. Singh (Manchester, United Kingdom), J. Wedzicha (London, United Kingdom), R. Trivedi (Durham, NC, United States of America), E. St Rose (Morristown, NJ, United States of America), S. Ballal (Morristown, NJ, United States of America), J. Mclaren (Gaithersburg, MD, United States of America), P. Darken (Morristown, NJ, United States of America), M. Aurivillius (Gothenburg, Sweden), C. Reisner (Morristown, NJ, United States of America), P. Dorinsky (Durham, NC, United States of America)
| |
Involvement of airway eosinophilia and airway hyperresponsiveness in management and therapy for COPD>
H. Kume (Sennan, Japan), M. Hojo (Tokyo, Japan), N. Hashimoto (Nagoya, Japan)
| |
TREATMENT-RELATED DETERMINANTS OF THE RESPIRATORY MICROBIOME IN COPD
E. Monso Molas (Sabadell, Spain), K. Opron (Ann Arbor, United States of America), O. Sibila (Barcelona Arbor, Spain), R. Faner (Barcelona Arbor, Spain), T. Gabaldon (Barcelona Arbor, Spain), L. Perea (Barcelona Arbor, Spain), S. Quero (Madrid, Spain), A. Marin (Badalona, Spain), M. Dominguez Alvarez (Barcelona, Spain), M. Garcia Núñez (Sabadell, Spain), Y. Huang (Ann Arbor, United States of America)
| |
Response to inhaled corticosteroids in patients with non-asthmatic eosinophilic bronchitis
K. Bialek-Gosk (Warszawa, Poland), M. Dabrowska (Warszawa, Poland), E. Grabczak (Warszawa, Poland), O. Truba (Warszawa, Poland), A. Rybka-Fraczek (Warszawa, Poland), K. Klimowicz (Warszawa, Poland), R. Krenke (Warszawa, Poland)
| |
Ensifentrine added on to tiotropium significantly improves lung function, symptoms and QoL in symptomatic COPD patients regardless of baseline reversibility
K. Rickard (London, United Kingdom), T. Bengtsson (Lund, Sweden), T. Rheault (London, United Kingdom)
| |
Triple therapy de-escalation to dual bronchodilation in COPD patients: Baseline data from the DACCORD cohort
H. Worth (Fürth, Germany), R. Buhl (Mainz, Germany), P. Kardos (Frankfurt, Germany), V. Obermoser (Nürnberg, Germany), E. Gückel (Nürnberg, Germany), C. Vogelmeier (Marburg, Germany), C. Criée (Bovenden, Germany)
| |